NCT05838638 Serious Gaming for Chemotherapy-induced Nausea and Vomiting
| NCT ID | NCT05838638 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Central Florida |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 610 participants |
| Start Date | 2023-06-09 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 610 participants in total. It began in 2023-06-09 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer. Participants will be randomized to either an intervention or control group. Outcomes such as symptom severity, quality of life, and resource use will be examined.
Eligibility Criteria
Inclusion Criteria: * age 60 or older * newly diagnosed with cancer * treatment with any chemotherapeutic agent of moderate or high emetic potential * on a 2, 3 or 4 week treatment cycle * proficient in English * has a telephone Exclusion Criteria: * previous diagnosis and/or treatment for cancer * end stage disease with less than 6 months to live * visually or hearing impaired without corrective device
Contact & Investigator
Victoria Loerzel, PhD
PRINCIPAL INVESTIGATOR
University of Central Florida
Frequently Asked Questions
Who can join the NCT05838638 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05838638 currently recruiting?
Yes, NCT05838638 is actively recruiting participants. Contact the research team at victoria.loerzel@ucf.edu for enrollment information.
Where is the NCT05838638 trial being conducted?
This trial is being conducted at Miami, United States, Orlando, United States.
Who is sponsoring the NCT05838638 clinical trial?
NCT05838638 is sponsored by University of Central Florida. The principal investigator is Victoria Loerzel, PhD at University of Central Florida. The trial plans to enroll 610 participants.